Immunome (IMNM)
(Delayed Data from NSDQ)
$13.80 USD
-0.03 (-0.22%)
Updated May 20, 2024 04:00 PM ET
After-Market: $13.84 +0.04 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
IMNM 13.80 -0.03(-0.22%)
Will IMNM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IMNM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMNM
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
IMNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for April 4th
Company News for Apr 2, 2024
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
Other News for IMNM
Immunome Announces Completion of Purchase of Assets from Atreca
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
Immunome promotes Max Rosett to CFO
Immunome appoints CFO
Immunome’s Promising Pipeline and Strategic Positioning Affirm Buy Rating